Ignyta, Inc.
(NASDAQ : RXDX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.39%183.701.1%$863.52m
GILDGilead Sciences, Inc.
-0.26%80.730.9%$828.11m
CELGCelgene Corporation
0.99%94.781.2%$768.42m
JUNOJuno Therapeutics, Inc.
1.96%86.6513.5%$580.24m
BIIBBiogen Inc.
0.45%288.731.2%$512.21m
REGNRegeneron Pharmaceuticals, Inc.
-1.09%319.532.7%$396.39m
VRTXVertex Pharmaceuticals Incorporated
-1.66%158.311.9%$353.40m
ALXNAlexion Pharmaceuticals, Inc.
-0.45%118.312.0%$255.45m
NKTRNektar Therapeutics
1.41%84.636.0%$250.55m
ILMNIllumina, Inc.
0.01%226.583.5%$230.72m
BLUEBluebird Bio, Inc.
2.19%209.9516.1%$196.16m
AAgilent Technologies, Inc.
1.41%72.081.5%$178.08m
INCYIncyte Corporation
0.46%85.912.5%$154.84m
BMRNBioMarin Pharmaceutical Inc.
1.09%84.764.4%$122.49m
EXASExact Sciences Corporation
-0.40%47.8226.0%$117.70m

Company Profile

Ignyta, Inc. is a precision oncology biotechnology company that engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. It plans focus on two product candidates: entrectinib, a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors ROS1 and ALK proteins, which is in two Phase I/II clinical studies in molecularly defined patient populations for the treatment of solid tumors; and RXDX-103, a development program targeting the cell division cycle 7-related, or CDC7, protein kinase. The company was founded by Jonathan E. Lim on October 31, 2013 and is headquartered in San Diego, CA.